New Triple-Threat vaccine aims to shield seniors from three winter viruses

NCT ID NCT07295028

Ongoing Prevention Sponsor: Vicebio Australia Proprietary Limited Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated Apr 29, 2026 · Updated 12 times

Summary

This early-stage study tests a new vaccine called VXB-251 in 240 healthy adults aged 60-83. The vaccine is designed to protect against three viruses that can cause serious lung infections: RSV, hMPV, and PIV3. Researchers are checking if the vaccine is safe and how well it triggers the immune system, comparing it to placebos and other experimental vaccines.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Emeritus Research

Camberwell, Australia
Momentum Clinical Research

Darlinghurst, Australia
University of Sunshine Coast, South Bank

Brisbane, Australia
University of the Sunshine Coast

Morayfield, Australia
University of the Sunshine Coast, Sippy Downs

Sippy Downs, Australia
Veritus Research

Melbourne, Australia

Conditions

Explore the condition pages connected to this study.

HEALTHY PARTICIPANTS HEALTHY PARTICIPANTS LOWER RESPIRATORY TRACT DISEASE LOWER RESPIRATORY TRACT DISEASE